SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
Published by sab.bio. Opens in a new tab.
More news
- Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
- Ocean Capital Acquisition Corporation Prices $100 Million Initial Public Offering
- Aeon Acquisition I Corp. Announces Pricing of $125 Million Initial Public Offering
- Perimeter Medical Imaging AI Closes Life Offering